Rafael Holdings, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rafael Holdings, Inc. (RFL) on June 5, 2023, reporting events occurring on June 1, 2023. The Company is incorporated in Delaware and its Class B common stock trades on the New York Stock Exchange.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific corporate transaction.
Material Changes and Transaction Details
On June 1, 2023, Rafael Holdings, Inc. entered into a Securities Purchase Agreement with Cyclo Therapeutics, Inc. ("Cyclo"). Key terms include:
- Investment Amount: Aggregate purchase price of $5,000,000.
- Assets Acquired: 4,000,000 shares of Cyclo common stock and a warrant to purchase an additional 4,000,000 shares.
- Warrant Terms: Exercise price of $1.25 per share; exercisable for seven years from issuance.
- Board Representation: Cyclo agreed to appoint a designee of Rafael Holdings to its Board of Directors, in addition to Rafael's CEO, William Conkling.
- Registration Rights: Cyclo must file a registration statement for the resale of the shares and warrant underlying shares upon Rafael's request.
Conditions, Risks, and Outlook
The closing of the transaction is subject to standard conditions, specifically requiring Cyclo to obtain stockholder approval in accordance with Nasdaq Listing Rule 5635. No forward-looking guidance or management commentary regarding future financial performance is provided in this filing.
Investor Verification Checklist
- Verify the status of Cyclo Therapeutics' stockholder approval required for the transaction to close.
- Confirm the appointment of the Rafael Holdings designee to the Cyclo Board of Directors.
- Review the amended Registration Rights Agreement dated May 2, 2023, for specific filing timelines.
- Monitor Cyclo's stock price relative to the $1.25 warrant exercise price.